PRESS RELEASE -- FOR IMMEDIATE RELEASE

Contact:
Bortec Biomedical Ltd.
225, 604-1st ST SW
Calgary, AB T2P 1M7
Contact: Dr. Brett Schönekess, 403.237.8145

BORTEC BIOMEDICAL RECEIVES 510(K) SUBSTANTIAL EQUIVALENCE LETTER FROM US FDA FOR AMT-8 AND ACCESSORIES.

Calgary, AB, January 21, 2003 --- Bortec Biomedical Ltd. a medical device solutions provider based in Calgary, AB, has recently received a substantial equivalence determination from the US Food and Drug Administration for its flagship product, the AMT-8 allowing for expanded marketing potential and field of use.

Dr. Scott Day, President and CEO of Bortec Biomedical commented that "With Bortec achieving this milestone of substantial equivalence for our AMT-8 product, we are advancing the use of EMG into larger, clinically relevant settings. This will result in a bridge being created between cutting edge EMG research and its application in the clinical environment, leading to better patient care."

The AMT-8 is currently in use around the world in leading research laboratories utilizing electromyography (EMG) as a key component of their research. With the issuance of the FDA 510(k) substantial equivalence letter, Bortec will be able to expand its market presence into a number of clinically important settings involving a greater range of health care professionals.

For more information about Bortec Biomedical Ltd., please visit the website at www.bortec.ca or contact Dr. Brett Schönekess at 403.237.8145.

###